Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China a Priority for AstraZeneca

publication date: Mar 18, 2008

Expanding the presence of AstraZeneca in the Asia-Pacific region in general and China specifically is a priority for AstraZeneca, according to John Ramsey, AstraZeneca’s Vice President for Global Development. Ramsey stressed that AstraZeneca is interested in developing drugs that address the needs of China’s population. Toward that end, AstraZeneca has established its Innovation Center China (ICC), which began operations in 2007 and establishes relationships with China’s universities and medical centers. More details...

Stock Symbol: (NYSE: AZN)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital